Humacyte Stock Analysis
| HUMAW Stock | USD 1.50 0.09 5.66% |
Humacyte is overvalued with Real Value of 1.39 and Hype Value of 1.45. The main objective of Humacyte stock analysis is to determine its intrinsic value, which is an estimate of what Humacyte is worth, separate from its market price. There are two main types of Humacyte's stock analysis: fundamental analysis and technical analysis.
The Humacyte stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Humacyte is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Humacyte Stock trading window is adjusted to America/New York timezone.
Humacyte |
Humacyte Stock Analysis Notes
The company recorded a loss per share of 3.16. Humacyte had not issued any dividends in recent years. To learn more about Humacyte call the company at 919 313 9633 or check out https://www.humacyte.com.Humacyte Investment Alerts
| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Faces Financial Uncertainty Potential Impact on Share Price and Capital - MSN |
Humacyte Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Management Efficiency
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.5081) %, meaning that it generated substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.96 in 2024. At this time, Humacyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 46.6 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.82).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.13 | 0.14 | |
| Tangible Book Value Per Share | 0.13 | 0.14 | |
| Enterprise Value Over EBITDA | (2.81) | (2.67) | |
| Price Book Value Ratio | 21.68 | 22.77 | |
| Enterprise Value Multiple | (2.81) | (2.67) | |
| Price Fair Value | 21.68 | 22.77 | |
| Enterprise Value | 271.4 M | 284.9 M |
Evaluating the management effectiveness of Humacyte allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Humacyte Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.466 | Return On Assets (0.53) | Return On Equity (8.51) |
Technical Drivers
As of the 27th of November, Humacyte retains the Risk Adjusted Performance of (0.01), standard deviation of 7.09, and Market Risk Adjusted Performance of (0.22). Humacyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Humacyte variance and potential upside to decide if Humacyte is priced fairly, providing market reflects its last-minute price of 1.5 per share. Please also validate Humacyte jensen alpha, which is currently at (0.25) to confirm the company can sustain itself at a future point.Humacyte Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Humacyte middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Humacyte. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Humacyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Humacyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Humacyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Humacyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Niklason Laura E over three months ago Disposition of 2625000 shares by Niklason Laura E of Humacyte at 2.75 subject to Rule 16b-3 | ||
Heather Prichard over three months ago Acquisition by Heather Prichard of 136000 shares of Humacyte subject to Rule 16b-3 | ||
Wallace Max N. over six months ago Disposition of 6564 shares by Wallace Max N. of Humacyte at 1.19 subject to Rule 16b-3 | ||
Heather Prichard over six months ago Disposition of 6564 shares by Heather Prichard of Humacyte subject to Rule 16b-3 |
Humacyte Predictive Daily Indicators
Humacyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Humacyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 364.77 | |||
| Daily Balance Of Power | (1.80) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 1.52 | |||
| Day Typical Price | 1.51 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.09) |
Humacyte Forecast Models
Humacyte's time-series forecasting models are one of many Humacyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Humacyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Humacyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Humacyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Humacyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Humacyte. By using and applying Humacyte Stock analysis, traders can create a robust methodology for identifying Humacyte entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.88) | (7.22) | |
| Operating Profit Margin | (62.15) | (65.26) | |
| Net Profit Margin | 36.93 | 38.78 | |
| Gross Profit Margin | (3.85) | (4.04) |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Humacyte to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.